PMID- 31020037
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 13
DP  - 2019 Jun 28
TI  - Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating 
      Conventional Treatment.
PG  - 67-81
LID - 10.1016/j.omto.2019.03.007 [doi]
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells and are the 
      key initiator of tumor-specific immune responses. These characteristics are 
      exploited by DC therapy, where DCs are ex vivo loaded with tumor-associated 
      antigens (TAAs) and used to induce tumor-specific immune responses. 
      Unfortunately, clinical responses remain limited to a proportion of the patients. 
      Tumor characteristics and the immunosuppressive tumor microenvironment (TME) of 
      the tumor are likely hampering efficacy of DC therapy. Therefore, reducing the 
      immunosuppressive TME by combining DC therapy with other treatments could be a 
      promising strategy. Initially, conventional cancer therapies, such as 
      chemotherapy and radiotherapy, were thought to specifically target cancerous 
      cells. Recent insights indicate that these therapies additionally augment tumor 
      immunity by targeting immunosuppressive cell subsets in the TME, inducing 
      immunogenic cell death (ICD), or blocking inhibitory molecules. Therefore, 
      combining DC therapy with registered therapies such as chemotherapy, 
      radiotherapy, or checkpoint inhibitors could be a promising treatment strategy to 
      improve the efficacy of DC therapy. In this review, we evaluate various clinical 
      applicable combination strategies to improve the efficacy of DC therapy.
FAU - Belderbos, Robert A
AU  - Belderbos RA
AD  - Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands.
AD  - Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the Netherlands.
FAU - Aerts, Joachim G J V
AU  - Aerts JGJV
AD  - Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands.
AD  - Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the Netherlands.
FAU - Vroman, Heleen
AU  - Vroman H
AD  - Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands.
AD  - Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190327
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC6475716
OTO - NOTNLM
OT  - checkpoint inhibitors
OT  - chemotherapy
OT  - dendritic cell-based therapy
OT  - immunogenic cell death
OT  - immunotherapy
OT  - macrophages
OT  - myeloid-derived suppressor cells
OT  - radiotherapy
OT  - regulatory T cells
OT  - tumor microenvironment
EDAT- 2019/04/26 06:00
MHDA- 2019/04/26 06:01
PMCR- 2019/03/27
CRDT- 2019/04/26 06:00
PHST- 2019/04/26 06:00 [entrez]
PHST- 2019/04/26 06:00 [pubmed]
PHST- 2019/04/26 06:01 [medline]
PHST- 2019/03/27 00:00 [pmc-release]
AID - S2372-7705(19)30037-3 [pii]
AID - 10.1016/j.omto.2019.03.007 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2019 Mar 27;13:67-81. doi: 10.1016/j.omto.2019.03.007. 
      eCollection 2019 Jun 28.